Physician profile

Michael A Brown

Cardiovascular Disease · Walnut Creek, CA

NPI 1093719056

$7,922.47

in general payments reported to CMS, 2019-2025

35 companies · $757 in 2025

The $757 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,483.78

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biotronik INC. $1,501.45 2019-2024 Solia, Acticor 7 Vr-T Dx, Biomonitor
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $648.81 2019-2025 Lifevest
Amarin Pharma, INC. $565.53 2020-2021
Abbott Laboratories $411.59 2019-2025 Cardiomems, Gallant, Assurity
Novartis Pharmaceuticals Corporation $407.35 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $390.44 2021-2024 Jardiance
E.R. Squibb & Sons, L.L.C. $360.24 2019-2025 Camzyos, Eliquis
Amgen INC. $349.25 2019-2025 Repatha, Repatha
Atricure, INC. $340.93 2021-2025 Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System
Impulse Dynamics (USA) INC. $340.32 2022-2023 Optimizer
Heartflow, INC. $319.97 2020-2025 Ffrct
Philips North America LLC $268.49 2024-2025 (5044) Mcot, Mcot
Janssen Pharmaceuticals, INC $260.59 2019-2023 Xarelto
Bayer Healthcare Pharmaceuticals INC. $259.82 2022-2025
Novo Nordisk INC $253.60 2021-2023 Rybelsus, Ozempic
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $226.17 2019-2023
Boston Scientific Corporation $195.43 2019-2025 Bodyguardian, Watchman Flx
Sanofi-Aventis U.S. LLC $148.95 2021-2024
Astrazeneca Pharmaceuticals LP $89.15 2022-2025 Wainua
Merck Sharp & Dohme LLC $77.29 2022-2024 Verquvo
Kiniksa Pharmaceuticals International, Plc $69.38 2024 Arcalyst
Medtronic, INC. $54.45 2025 Affera Mapping System
Cathworks, INC. $50.02 2019-2020
Lexicon Pharmaceuticals, INC. $47.53 2023-2024 Inpefa
Actelion Pharmaceuticals US, INC. $42.67 2022
Esperion Therapeutics, INC. $37.61 2024-2025 Nexletol
Alnylam Pharmaceuticals INC. $31.76 2024 Amvuttra
Kestra Medical Technology Services, INC. $30.35 2022
Medtronic Vascular, INC. $25.55 2019-2020
Daiichi Sankyo INC. $24.80 2023 Injectafer
Regeneron Healthcare Solutions, INC. $22.15 2024 Evkeeza
Edwards Lifesciences Corporation $20.60 2023 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Scpharmaceuticals INC. $18.38 2025
Inspire Medical Systems, INC. $17.72 2023 Inspire
Abiomed $14.13 2024 Impella

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael A Brown

$7,922.47

in general payments reported 2019-2025

Years
2019-2025
Top company
Biotronik INC.
Context
The $757 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/139686/michael-a-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.